Information  X 
Enter a valid email address

Mereo BioPharma Grp (MPH)

  Print   

Friday 09 October, 2020

Mereo BioPharma Grp

Director/PDMR Shareholding

RNS Number : 6911B
Mereo BioPharma Group plc
09 October 2020
 

Mereo BioPharma Group plc

Director and PDMR Dealings

 

London and Redwood City, Calif ., October 9, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 7 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 12,711 American Depositary Shares (ADSs) at a price of USD 2.36 per ADS, Brian Schwartz, Non-Executive Director of Mereo, purchased 20,000 ADSs at a price of USD 2.35 per ADS and John Richard, Head of Corporate Development of Mereo, purchased 6,500 ADSs at a price of USD 2.36 per ADS.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

Denise Scots-Knight

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD 2.36

12,711

 

 

d)

Aggregated information:  volume, Price

30043.72

e)

Date of the transaction

2020-10-07

f)

Place of the transaction

XNMS

 

1

Details of the person discharging managerial responsibilities

a)

Name

Brian Schwartz

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD 2.35

20,000

 

 

d)

Aggregated information:  volume, Price

47068.00

e)

Date of the transaction

2020-10-07

f)

Place of the transaction

XNMS

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD 2.36

6,500

 

 

d)

Aggregated information:  volume, Price

15330.06

e)

Date of the transaction

2020-10-07

f)

Place of the transaction

XNMS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEKLFBBBLBFBZ

a d v e r t i s e m e n t